PharmaJet is raising a Series H round with terms similar to the last raise except this round will be $7-15 million and RVC has about a $300K pro-rata allocation. Since this allocation can be used by any RVC investor, with first rights going to current PharmaJet Investment Group members, we're holding a deep dive session with Heather Potters from PharmaJet to help learn about this raise, what the milestones will be, new updates on drug pipeline for PharmaJet, and current exit strategy outlook.
This will be a session with a short presentation and then time for Q&A, so bring your questions.
RVC investors who register for this event will be provided with a link to the term sheet and other documents related to the raise embedded in your confirmation email, so you'll have a chance to do a little homework before the call.
As a matter of historical perspective, RVC has invested in eight rounds with PharmaJet and have been supporting the company for almost eight years. This is one of those companies we did not want an early exit for since it takes time for the regulatory process and we're finally seeing the outcomes we had hoped for in terms of value creation, so this could be a good time to invest.
From Heather: "This meeting will be reserved to update RVC investors about PharmaJet's latest progress and investment round in closing with a strategic partner, which includes co-investment rights for our investors."